Fabbro, Michel <br/><br/>
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.  [electronic resource] 

 -  Gynecologic oncology  03 2019 
 - 560-567 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2018.12.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Female<br/>Humans<br/>Indazoles--adverse effects<br/>Maintenance Chemotherapy<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Patient Reported Outcome Measures<br/>Piperidines--adverse effects<br/>Poly(ADP-ribose) Polymerase Inhibitors--adverse effects